Search results
Results from the WOW.Com Content Network
[8] [9] It was developed as a recombinant protein (rhIL-11) as the drug substance oprelvekin. The human IL-11 gene, consisting of 5 exons and 4 introns, is located on chromosome 19, [6] and encodes a 23 kDa protein. IL-11 is a member of the IL-6-type cytokine family, distinguished based on their use of the common co-receptor gp130.
LMT-28 is an experimental drug which was the first molecule discovered that acts as an antagonist of IL6R, the receptor for Interleukin-6, and so blocks its activity in the body. Interleukin-6 is a cytokine signalling molecule which plays a key role in inflammation, so blocking IL6R is useful for alleviating a number of disease processes in ...
Interleukin 11 (IL-11) is a secreted protein that stimulates megakaryocytopoiesis, initially thought to lead to an increased production of platelets (it has since been shown to be redundant to normal platelet formation), as well as activating osteoclasts, inhibiting epithelial cell proliferation and apoptosis, and inhibiting macrophage mediator ...
They act by inhibiting gene expression of cytokines including Interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, and TNF-alpha by binding to corticosteroid response elements on DNA. [1] This decrease in cytokine production reduces T cell proliferation. With decreased T cell proliferation there is decreased production of IL-2.
Oprelvekin is recombinant interleukin eleven (IL-11), [1] a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
Interferon type II (IFN-γ in humans): This is also known as immune interferon and is activated by Interleukin-12. [3] Type II interferons are also released by cytotoxic T cells and type-1 T helper cells. However, they block the proliferation of type-2 T helper cells.
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [ 1 ] Hence, anti-IL6 agents have been sought.
[11] Biallelic deleterious mutations in the IL1RN gene results in a rare autoinflammatory disease called deficiency of the interleukin-1–receptor antagonist (DIRA). [12] Variants of the IL1RN gene is also associated with risk of schizophrenia. [13] [14] Elevated levels of IL-1RA has been found in serum of schizophrenia patients. [15]